Swan Capital’s GT Biopharma GTBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-40
Closed -$785 – 583
2025
Q4
$785 Buy
+40
New +$710 ﹤0.01% 424

Other funds holding GTBP

Swan Capital's GTBP Position: Q1 2026 in Review

Swan Capital sold out of GT Biopharma (GTBP) in Q1 2026, closing a stake of 40 shares — an estimated $785 sold.

Swan Capital first reported a position in GTBP in Q4 2025 and held it in 1 quarter. The position peaked at $785 in Q4 2025. 40 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Swan Capital reported no remaining GT Biopharma position as of Q1 2026 after selling out during the quarter.
  • Swan Capital sold 40 GT Biopharma shares in Q1 2026, an estimated $785.
  • Swan Capital first reported a position in GT Biopharma in Q4 2025 and held it in 1 quarter.
  • Swan Capital's GT Biopharma position peaked at $785 in Q4 2025.
  • 40 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Swan Capital's 13F filing for Q1 2026, filed 14 May 2026.